$143.630
-2.542 (-1.77%)收盤時
NOVT 資訊
NOVT 事件
Novanta Reports Q2 Revenue of $265.8 Million
Reports Q2 revenue $265.8M, consensus $262.3M. "Novanta delivered an exceptional second quarter, exceeding expectations across revenue, margins, and profitability," said Matthijs Glastra, Chair and Chief Executive Officer. "Revenue increased 10.3% year-over-year to $266 million on a reported basis and grew 9.3% organically, marking our strongest organic growth quarter since the first quarter of 2023. We also delivered a strong Adjusted Gross Margin of 47%, and generated Adjusted EBITDA of $60.7 million, a 16.4% increase year-over-year, representing an Adjusted EBITDA margin of 22.8%."
Sees Q3 Revenue of $300M-$304M
Sees Q3 revenue $300M-$304M, consensus $262.82M. Sees Q3 adjusted EBITDA $74M-$77M.
Sees FY26 Revenue of $1.13B-$1.14B
Sees FY26 revenue $1.13B-$1.14B, consensus $1.05B. Sees adjusted EBITDA $273M-$278M.
Novanta Completes Acquisition of Riverpoint Medical
Novanta announced that it has completed the acquisition of Riverpoint Medical from Arlington Capital Partners. The transaction is expected to generate a high single-digit return on invested capital by year three, achieve the Company's return hurdle rate by year five, and be immediately accretive to Novanta's organic growth, adjusted gross margins, adjusted EBITDA growth and margins, and cash flows. The acquisition is also expected to contribute $0.18 to $0.25 of adjusted earnings per share in 2027, the first full year after the close, with additional detail on the impact to Novanta's 2026 financials to be provided on the upcoming second quarter earnings call. Riverpoint Medical will be reported under Novanta's Medical Solutions operating segment.
Selling Stockholders Plan to Sell 2.14M Common Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.14M common shares. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。